Navigation Links
FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
Date:3/3/2009

- Agency Supports Company's Production and Clinical and Preclinical Plans for DXL625 -

- Live Teleconference Scheduled with Leadership and Scientific Team for March 04, 2009 -

BRITISH COLUMBIA, Canada March 3 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (Toronto Stock Exchange: IXS.V), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces the United States Food & Drug Administration (FDA) has completed its comprehensive review of the development plans for InNexus' lead preclinical candidate, DXL625 (CD20) for the prospective treatment of Non-Hodgkin's Lymphoma (NHL) and/or Chronic Lymphocytic Leukemia (CLL).

InNexus' submission included detailed information on plans for a Phase I clinical program, preclinical pharmacology and toxicology data and its current manufacturing. At the Pre-IND meeting, FDA supported InNexus' current manufacturing plans stating that the plans were suitable for the manufacture of Phase I product of DXL625 onsite at InNexus. FDA also reviewed completed animal testing and recommended a more expeditious design for the final animal studies to set the stage for human studies. Per these recommendations, InNexus foresees no regulatory impediment to the initiation of human clinical studies in early 2010.

"We are pleased to announce the completion of our pre-IND meeting with the FDA," said Dr. Jur Strobos, Vice President of Clinical & Regulatory Affairs of InNexus. "We appreciate the thorough review and clear support from FDA for our product development plan. Their review was detailed and comprehensive. As a result, we are particularly pleased that we have affirmation of a clear, simple, and rapid path for DXL625 use in human Phase I trials. Additional pre-clinical testing and analysis will be conducted over the coming months to move us along this path
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CardioDynamics Provides 2007 Shareholder Meeting Update
2. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
3. NxStage Medical Provides Update on Medisystems Acquisition
4. VaxGen Files 2006 Financial Statements and Provides Cash Update
5. Signalife Provides Corporate Update
6. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
7. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
8. SGX Provides Update on BCR-ABL Collaboration
9. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
10. Pressure BioSciences, Inc. Provides Corporate Update
11. New Scrip Report Provides Strategic Insight on the Burgeoning Biosimilars Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Global Resorcinol Market ... industry insights on the global resorcinol industry. The report highlights the various growth ... market scenarios and analysis of primary and secondary inputs from the existing players ...
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
Breaking Biology Technology:Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... DIEGO, May 12 Amylin Pharmaceuticals, Inc. (Nasdaq: ... Care Conference on Tuesday, May 19, 2009 at ... Daniel M. Bradbury, president and chief executive officer of Amylin ... session will be webcast, and a recording will be made ...
... 12 Joseph F. Finn, Jr., C.P.A. ("Finn"), ... have been assigned to him for the benefit of ... molecule designed to inhibit the activity of galectin-3, a ... of human cancers and whose over-expression is associated with ...
... wide array of ACCU-CHEK programs centered around Behavior ... better self-care.INDIANAPOLIS, May 12 Roche, the maker ... pumps, announced today its long-term commitment to tackle ... Change through Patient Engagement (SM) program - a ...
Cached Biology Technology:Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors 2Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes 2Roche Announces Long-Term Commitment to Tackle Growing Epidemic of Diabetes 3
(Date:7/31/2015)... de julio de 2015 La 10 th ... por medio de BGI del 22 al 25 de octubre de ... Este año, la conferencia celebra su décimo aniversario. Desde ... en una de las reuniones anuales más influyentes del mundo ... reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, ... for gene function analysis and biomarker discovery, announced ... (sgRNA) Knockout Library targeting all human protein coding ... permanently "knock out" a gene,s function. Cellecta,s new ... high throughput screening tool so that researchers can ...
(Date:7/23/2015)... July 23, 2015 Research and Markets ... the "Global Outlook of the Biometrics Industry ... The global biometrics market is likely ... commercial applications owing to the uptake of multiple ... transformation that enhances the growth of biometrics in ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... February 2, 2014, Shenzhen, China - Researchers from Yellow ... BGI-Shenzhen and other institutes have successfully decoded the first ... Cynoglossus semilaevis ), providing insights into ZW sex chromosome ... generated in this project also lay foundation on the ...
... cycles and there are also weight loss cycles. Almost ... weekends. What separates the slim from the heavy isn,t ... much they lose during the weekdays. In this study, ... researchers from the VTT Technical Research Centre of Finland ...
... on a daily basis that could lead to cancers ... system, Melbourne scientists have found. The research team ... the immune system was responsible for eliminating potentially cancerous ... developed into B-cell lymphomas (also known as non-Hodgkin,s lymphomas). ...
Cached Biology News:Two papers unraveled the mystery of sex determination and benthic adaptation of the flatfish 2Two papers unraveled the mystery of sex determination and benthic adaptation of the flatfish 3Two papers unraveled the mystery of sex determination and benthic adaptation of the flatfish 4Whether your lose or gain weight depends on weekdays 2Red alert: Body kills 'spontaneous' blood cancers on a daily basis 2
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
... processes up to 48 lanes, 24 bi-directional, ... can be from either slab gel or ... chemistries. The detection parameters in Explorer have ... consistency. We have built Explorer for ...
... ISO 9001:2000 Certified USDA Research Registered ... SOP's Training AALAS Certified Technicians ... Procedures GLP Documentation Upon Request Focus ... point for all your custom immunology service ...
...
Biology Products: